Your privacy is very important to us.When you visit our website,please agree to the use of all cookies.For more information about personal data processing,please go to Privacy Statement.

  • e1banner01.jpg e1banner01ph.jpg

    Partnership

Business Development

We Partner With Biotech And Biopharma Companies Globally To Capture And Develop Innovative Therapies That Address Critical Unmet Needs Of Patients In China And Asia


Our Business Development Effort Focuses On Forging Collaborations With Leading Partners In The Ecosystem To Deliver Innovative Therapies To patients In Asia-Pac Region

e1ig1.jpg

Our Partners

  • Verona Pharma

    e1logo01.png

    Verona Pharma

    Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs, including COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

  • Aerogen Pharma

    AerogenPharma.png

    Aerogen Pharma

    Aerogen Pharma is an Irish specialty pharmaceutical company developing inhaled products for quick, efficient, consistent and user-friendly treatment of critically ill patients in hospital acute care. Aerogen Pharma improves existing drugs by targeting them to the lung using a proprietary, high performance aerosol delivery system based on the market-leading nebulizer technology created by its parent organization, the Aerogen group. For more information, visit www.aerogenpharma.com.

  • Altamira Therapeutics

    AltamiraTherapeutics.png

    Altamira Therapeutics

    Altamira Therapeutics (NASDAQ: CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne allergens and, where approved, viruses (Bentrio™; commercial) or for the treatment of vertigo (AM-125; post Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). 

    Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit www.altamiratherapeutics.com.


    Nuance Pharma launched Bentrio™ nasal spray in Hong Kong since November 2022. For more information, please visit Bentrio™. 

  • Neumentum

    Neumentum.png

    Neumentum

    Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management, without the risks for abuse, misuse and diversion seen with opioids or the opioid-induced side effects, including potentially life-threatening respiratory depression. 

    Neumentum is led by an experienced executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.neumentum.com.

  • DKSH

    DKSH.png

    DKSH

    DKSH's purpose is to enrich people's lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. 

    DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,920 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. For more information, please visit www.dksh.com/hec.

CONTACT

Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040

Copyright 2023 NUANCE BIOTECH reserved. 沪ICP备17029781号-4